Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases

Urology. 2004 Feb;63(2):321-6. doi: 10.1016/j.urology.2003.09.044.

Abstract

Objectives: To investigate the prognostic value of some conventional bone markers and a number of other factors in terms of the survival of patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.

Methods: The data of 141 patients were analyzed to verify the influence of the following factors on survival: bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, the urinary calcium/creatinine ratio, patient age, Karnofsky performance status, pathologic grade, duration of response to primary hormonal therapy, prostate-specific antigen, hemoglobin, lactate dehydrogenase, and extent of bone disease.

Results: When all the variables were simultaneously analyzed using the multivariate proportional hazard model, only Karnofsky performance status (P <0.005) and duration of response to primary hormonal therapy (P <0.0001) remained statistically significant.

Conclusions: The results of this study suggest that bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, and the urinary calcium/creatinine ratio are not prognostic of survival in patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / mortality
  • Adenocarcinoma / secondary*
  • Aged
  • Alkaline Phosphatase / blood*
  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Biomarkers, Tumor / blood*
  • Bone Neoplasms / blood
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / mortality
  • Bone Neoplasms / secondary*
  • Calcium / urine
  • Collagen / blood*
  • Collagen Type I
  • Creatinine / urine
  • Drug Resistance, Neoplasm
  • Follow-Up Studies
  • Humans
  • Italy / epidemiology
  • Karnofsky Performance Status
  • Life Tables
  • Male
  • Middle Aged
  • Peptides / blood*
  • Phosphopeptides / blood*
  • Procollagen / blood*
  • Proportional Hazards Models
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / mortality
  • Survival Analysis
  • Time Factors

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Collagen Type I
  • N-propeptide type I collagen
  • Peptides
  • Phosphopeptides
  • Procollagen
  • collagen type I trimeric cross-linked peptide
  • Collagen
  • Creatinine
  • Alkaline Phosphatase
  • Calcium